How to Inject ARA-290

Why Subcutaneous Injection? Understanding the Route of Administration

ARA-290 is a peptide—a chain of amino acids vulnerable to stomach acid and digestive enzymes. Oral delivery destroys it; intravenous (IV) injection is impractical for home self-administration and carries infection/thrombosis risk. Subcutaneous (SubQ) injection—into the fatty tissue layer between skin and muscle—is the optimal route because it:

• Delivers the intact peptide to systemic circulation without degradation
• Provides a subcutaneous depot that sustains absorption over 30-60 minutes (smoother pharmacokinetics than IV bolus)
• Allows safe self-administration with minimal training
• Minimizes systemic exposure compared to IM (intramuscular), reducing whole-body side effects
• Has lower infection risk than IV lines

Clinical trial participants self-injected ARA-290 for weeks to months without serious complications, validating SubQ as the standard route for research and clinical use.

Needle Selection: Gauge, Length, and Syringe Specifications

Needle Gauge: ARA-290 is typically injected using 27-31 gauge needles. This range balances several factors:

• 27 gauge: Thicker, lower insertion resistance. Best for first-time injectors; causes minimal pain. Allows faster infusion (1-2 second delivery time). Standard choice.
• 29 gauge: Medium thickness. Balanced pain/resistance trade-off. Used when tolerance for thicker needles is low.
• 31 gauge: Thinnest available. Minimal pain but slower infusion, requires 3-5 second delivery time. Used by needle-sensitive individuals.

Needle Length: 5/8 inch (approximately 16mm) is standard for SubQ injection in adults. This length is long enough to reach subcutaneous tissue (typically 5-10mm below skin surface) without penetrating muscle (which is 10-15mm below skin in most anatomical areas). Do not use longer needles (e.g., 1 inch, which is for IM injection).

Syringe Size: 3 mL syringes are standard for ARA-290 dosing. A 3 mL syringe allows accurate measurement of 2-4 mg doses reconstituted to typical concentrations (2 mg/mL). Some users prefer 1 mL syringes if precise dosing of very small volumes is desired (e.g., 0.5 mL = 1 mg if concentrated to 2 mg/mL).

Needle-Syringe Compatibility: Ensure the needle fits your syringe (standard Luer-lock 23mm threading for SubQ).

Injection Site Selection and Rotation Protocol

ARA-290 can be injected into several subcutaneous sites. Rotation between sites prevents lipodystrophy (fatty tissue damage) and local inflammation from repeated injections.

Primary Sites (Preferred):

• Abdomen: Pinch the skin and fat around the navel, inject perpendicular to skin. Excellent absorption; minimal pain. Avoid the periumbilical area (within 2 inches of navel) due to variable tissue depth.
• Anterior/lateral thigh: Pinch the outer thigh between knee and hip. Good absorption; easy to visualize. Pain slightly higher than abdomen for some individuals.

Secondary Sites (Acceptable but Less Common):

• Buttocks: Upper outer quadrant. Good absorption; high fat content. Less visible if needed for privacy. Harder to reach yourself; more suitable if partner administers injection.
• Upper arm (triceps region): Pinch the back of the arm. Lower fat content; requires more careful technique to ensure SubQ placement. Acceptable but not preferred.

Avoid: Areas with scar tissue, active infection, excessive bruising, or tattoos. Do not inject over bones, major blood vessels, or nerve pathways.

Rotation Pattern (28-day cycle):

• Days 1-7: Abdomen (right side)
• Days 8-14: Abdomen (left side)
• Days 15-21: Right thigh
• Days 22-28: Left thigh
• (Repeat pattern if continuing beyond 28 days)

This systematic rotation ensures no site is used more than once per 28 days, minimizing local complications.

Step-by-Step Injection Protocol

Preparation (1-2 minutes before):

1. Gather supplies: Reconstituted ARA-290 vial, syringe, needle, alcohol prep pad, ice pack (optional), warm compress (optional).
2. Verify dose: Double-check the vial label (mg amount) and confirm your calculated injection volume (e.g., if 2 mg/mL and you need 2 mg, draw 1 mL).
3. Draw the peptide: Using an 18-20 gauge drawing needle (larger needle for easier drawing from vial), withdraw the calculated volume into the syringe. Draw air into the syringe equal to the volume you will withdraw, inject air into the vial to equalize pressure, then draw the peptide. Replace the drawing needle with your 27-31 gauge injection needle.
4. Remove air bubbles: Gently tap the syringe to consolidate any bubbles, then expel air into a sharps container (not back into the vial). A small bubble (<0.1 mL) is acceptable.
5. Verify no leakage: Wipe the injection needle with a clean tissue (do not use alcohol—it degrades peptides); ensure no dripping occurs.

Site Preparation (2-3 minutes before):

1. Sanitize: Clean the injection site with an alcohol prep pad using a circular motion (center outward) for at least 30 seconds. Allow to air-dry (alcohol must evaporate; injecting through wet alcohol increases pain).
2. Optional: Ice the site: Applying ice for 3-5 minutes numbs the skin, reducing needle pain. Allow skin to warm slightly before injection if you ice.

Injection (5-10 seconds):

1. Pinch the skin: Between your thumb and forefinger, gently gather 1-2 inches of skin and subcutaneous fat. This ensures you have adequate tissue to inject into and reduces risk of intramuscular placement.
2. Insert the needle: Hold the syringe at a 45-degree angle to the skin. Quickly insert the needle with one smooth motion until it is fully embedded (you should feel a slight resistance change as the needle penetrates skin and enters fat).
3. Inject slowly: Push the plunger steadily over 2-3 seconds (for 27-29 gauge needles) or 3-5 seconds (for 31 gauge). Do not rush; rapid infusion increases pressure and can cause burping back (peptide leakage up the injection tract).
4. Withdraw the needle: Once the full dose is infused, pause 1-2 seconds, then smoothly withdraw the needle at the same 45-degree angle.
5. Apply pressure: Gently press the injection site with a clean tissue for 5-10 seconds to prevent bleeding and peptide leakage.

Post-Injection (1-5 minutes after):

1. Optional: Apply warmth: A warm (not hot) compress applied for 3-5 minutes after injection improves blood flow and facilitates subcutaneous absorption. Some users skip this; it is optional.
2. Observe the site: Check for bleeding. Mild oozing is normal; excessive bleeding suggests inadvertent small vessel puncture (press 1-2 minutes longer). Bruising develops over hours; normal.
3. Dispose of sharps: Place the used needle and syringe in a sharps container (never reuse). Do not throw into regular trash.
4. Record the injection: Note in a calendar or app which site was injected, which vial used, and any unusual reactions (this aids troubleshooting if problems occur).

Managing Injection Site Reactions

Injection site reactions are the most common ARA-290 side effect. Prevention and management strategies:

Prevention:

• Rotate injection sites faithfully (no site more than once per 28 days)
• Use proper sterile technique (alcohol prep, clean needle)
• Ensure needle is truly subcutaneous (not intradermal, not intramuscular)
• Inject slowly (2-3 seconds minimum) to avoid pressure buildup
• Apply ice before and/or warmth after to improve vascular response
• Stay well-hydrated (dehydration increases local inflammatory response)

If Reaction Occurs:

• Mild erythema and edema (typical): Appears 15 minutes to 2 hours post-injection. Resolves within 24-48 hours. Ice for 10 minutes immediately post-injection; apply hydrocortisone cream (1%) if itching develops. Continue injections at different sites; reactions do not indicate allergic response.
• Significant swelling or warmth: Indicates inflammation. After ruling out infection (no fever, no increasing redness/drainage), ice for 15 minutes, elevate the limb, and consider applying NSAIDs topically. Usually resolves in 24-72 hours. Report to clinician if worsening after 72 hours.
• Infection signs (fever, purulent drainage, increasing warmth, spreading redness): Rare but requires medical attention. Stop injections, seek urgent care. Bacterial skin infection at injection site is treatable with oral or topical antibiotics.
• Severe allergic reaction (hives, angioedema, dyspnea): Extremely rare with ARA-290. Seek emergency care immediately. Do not re-use ARA-290 if allergic reaction confirmed.

Common Injection Errors and How to Avoid Them

Error 1: Injecting into muscle (IM instead of SubQ)
Symptom: Sharp pain during injection, rapid muscle soreness.
Prevention: Pinch the skin/fat before injecting. Ensure needle insertion is at 45-degree angle (IM is perpendicular/90 degrees). Verify adequate fat at injection site before selecting it.
Fix: If you accidentally inject IM, finish infusing the dose (pulling out won't recover it). Next injection: select a different site with more fat, and pinch more generously.

Error 2: Injecting intradermally (into skin, not under it)
Symptom: Visible bleb (small raised bump) appears at injection site; severe local irritation.
Prevention: Insert needle fully (at least 3/8 inch for 5/8-inch needle) before pushing the plunger.
Fix: If you see a bleb forming during injection, stop, withdraw, and re-inject at an adjacent site after pinching more tissue together.

Error 3: Reusing needles
Risk: Needle dulling leads to pain; increased infection risk; peptide contamination.
Prevention: Always use a fresh needle for each injection. Do not reuse even if you injected yourself (sterile needle is mandatory).

Error 4: Injecting too quickly
Symptom: Sudden pain, possible backflow of peptide up the injection tract, localized bruising.
Prevention: Count to 2-3 while pushing the plunger. Slow is better.

Error 5: Skipping site rotation
Result: Lipodystrophy (fat damage), frequent injection site reactions, potential nodule formation.
Prevention: Use the rotation pattern described above. Mark each site on a calendar if needed.

Troubleshooting Common Injection Problems

Difficulty Reconstituting or Drawing from Vial
If the peptide powder takes longer than 5 minutes to dissolve, or if drawing from the vial is difficult despite pressure equalization, the vial may contain improperly lyophilized powder or moisture. Warm the vial gently in your palm (do not use direct heat) for 2-3 minutes and try again. If dissolution still fails, the product quality may be compromised; contact your vendor. Use only fresh bacteriostatic water; old or contaminated water dissolves less reliably.

Peptide Precipitation in Solution
If your reconstituted ARA-290 develops cloudiness hours or days after reconstitution (despite initial clarity), precipitation is occurring. This indicates bacterial growth, contamination, or inadequate bacteriostatic water preservation. Do not use precipitated solutions—discard and prepare a fresh vial. Prevent this by maintaining proper refrigeration (2–8°C) and strict sterile technique when drawing doses.

Bleeding or Excessive Bruising Post-Injection
Mild bruising is normal; significant bruising suggests small blood vessel puncture. Prevent by varying injection sites, avoiding areas with prominent blood vessels, and using appropriate needle insertion technique. If heavy bleeding occurs during injection, withdraw the needle, apply firm pressure for 2 minutes, and apply ice. Bruising that develops 30+ minutes post-injection indicates venous bleeding—elevate the limb and apply ice for 15 minutes. Contact a healthcare provider if bleeding persists beyond 5 minutes of pressure.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions